Lisa Pompa Email & Phone Number

Norfolk, Virginia Area

Launched first ever gene therapy (Luxturna) an inherited orphan disease in the National, Regional, and Blue’s Commercial payer space strategizing with C-suite level stakeholders to prepare for payment and delivery on complex one-time therapies. Leveraged 21st Century Cures Act to prepare for unencumbered access at approval through established label based medical policy. Worked cross functionally with Zone Leads, Patient Services, SP and Payer to support a positive patient journey in a complex payer/provider landscape. Executed on a National Blue’s Strategy connecting all 36 Blue’s to appropriate payment and delivery while supporting the value of the therapy over time through Outcomes Based Contracting. Account Expertise Blue Cross Blue Shield Association, HCSC, Prime Therapeutics, Federal Employee Plan, Magellan Rx, Express Scripts and multiple Blues across the US.Selected Accomplishments:• Achieved over 90% published reasonable medical policy, addressing access issues by partnering with Medical Affairs to reverse any initial negative policies.• Executed on adoptions of an “first of its kind” innovative payment model that will serve as a benchmark for gene therapy moving forward. Completing pricing agreements with select payers.• Led the Blue’s National Payer Strategy both internally with the Commercial Payer team and externally with implementation of Innovative Payment Model and Value Based Agreements as it relates to Blue Card and the coordination of services across both Home/Host plans.• Selected to present Gene Therapy Payment and Delivery Options at quarterly BCBS National Council of Physician and Pharmacist Executive Meeting attended by top pharmacy executives of 36 Blues plans.• Facilitated Executive Exchange between National Payers and Spark Executive team to identify strategic partnerships and long-term collaboration opportunities.

Selected to replace 1 of 4 National Account Directors to ensure optimal access for anti-VEGF EYLEA in National and select Regional healthcare payers. Primary accounts include UHC, Optum Rx, Prime Therapeutics, HCSC, Magellan Rx and BCBS FL, LA, AR, AL and TN. Activity includes problem solving reimbursement challenges for high cost buy & bill biologic injectable, working with senior level Pharmacy and Medical Directors to establish appropriate medical policy. This includes delivering strong clinical understanding of retinal disease as it relates to wet AMD and Diabetic Macular Edema and negotiating appropriate prior authorization criteria in collaboration with health plans as they build utilization management strategies for Ophthalmic injections . Work internally to build cross-functional collaboration with Market Access counterparts (Reimbursement Managers and Directors), RAMs, field team and internal corporate partners to ensure appropriate market coverage and support.

Mid-Atlantic States (Md, Dc, Va, Nc, Sc, Ky)

Recruited as 1 of 19 RAMs nationally (now 1 of 9) to the newly created commercial division to maximize share growth and attain access for Kalydeco (orphan Cystic Fibrosis drug) and Incivek (Hepatitis C) within Commercial, Managed Medicaid, FFS, Medicare Part D, Corrections, and Specialty Pharmacy accounts. Devise and execute pull-through strategies to enhance brand awareness in collaboration with marketing, sales management, and NAMs; communicate and partner with field sales force to implement marketing strategies. Key accounts include CareFirst, BCBS Federal Employees, Sentara / Optima, Amerigroup National, BCBS of NC, SC, and VA, and all State Medicaid programs.Selected accomplishments: ♦ Achieved 81% market share versus 72% national average and garnered 98% preferred / parity formulary access (preferred direct contracts at Sentara / Optima, Correct Rx, and Xerox Healthcare for Ohio Medicaid) for Incivek despite competitor launch during same period.♦ Increased Incivek sales volume 300% at DC Medicaid by developing a collaborative project to educate disease management staff to improve patient compliance through member interaction.♦ Launched and secured 100% access for Kalydeco in targeted payer accounts by developing relationships with key decision makers and implementing ground-breaking clinical education to ensure coverage through prior authorizations with appropriate label-driven criteria.♦ Recognized with the Platinum Vocap Award (Top 1% out of 2500 employees) in sales and outstanding contributions to the DC Medicaid Collaboration Project in 2012 and the Silver Team Vocap Award in 2014. ♦ Selected as Incivek Product Champion, charged with POA planning and executing workshops / presentations in partnership with internal marketing teams, as well as informing team members of challenges in the highly competitive HCV marketplace.♦ Honored with 3 HIRC awards for Best Account Manager MCO (2012, 2013) and Managed Medicaid Account Manager (2012).

Retained subsequent to Wyeth merger with Pfizer to negotiate contracts and secure formulary access, coverage, and reimbursement for full portfolio of biologics / small molecule products, including Lipitor, Lyrica, Celebrex, Enbrel, Premarin, Viagra, Genotropin, Relpax, Pristiq, Aricept, and Chantix with Commercial, Managed Medicaid, ACO, and Medicare Part D customers in the State of Virginia. Established and maintained strong, productive relationships with C-level executives and Medical / Pharmacy Directors to drive product access / utilization and negotiate win-win contracts. Collaborated with and lead field sales teams on implementing strategic pull-through action plans to maximize product access and communicate brand messaging strategies. Key accounts included Sentara / Optima, Amerigroup, Anthem BCBS of VA, Coventry-Southern Health, and Sentara Healthcare. Selected accomplishments: ♦ Renegotiated a 2-year, preferred formulary contract (only 1 of 2 in the country) for Enbrel with Sentara / Optima despite growing competition and lucrative discounting in the marketplace, which resulted in a $2 million revenue increase.♦ Realized $4.6 million in protected Enbrel sales by formulating a creative benefit design strategy enabling customers to achieve cost savings while preserving preferred access for Enbrel, which led to nomination for the Specialty Business Unit Commercial Award in 2010.♦ Negotiated and added Aricept 23 to Medicare and Commercial contracts with unrestricted access subsequent to previous no new additions to formulary at Sentara in previous 5 years. Renewed Commercial and Managed Medicaid contracts for Aricept, Viagra, and Xalatan.♦ Established 4 separate customer-centric initiatives in one payer value proposition within several divisions at Sentara / Optima.♦ Chosen as facilitator for ACO discussions between Sentara and Pfizer's IDS Strategy Lead. ♦ Recognized with the Top 10% Performer and the Vice President Management Cabinet (VPMC) Awards.

Appointed to formulate and execute the business development, marketing, contracting / contract compliance, and rebate strategies to achieve formulary access for Wyeth products within regional MCO and federal government (DOD / VA) accounts. Represented large product portfolio, including Enbrel, Protonix, Effexor XR, Altace, Zosyn, and Enbrel. Interfaced with C-level executives and Medical / Pharmacy Directors during presentations and contract negotiations. Collaborated with Brand Management, Sales Directors, and National Account Managers on pull-through initiatives and implemented programs at the field level. Developed Key Opinion Leaders to serve as product advocates and train field team on reimbursement strategies. Managed key accounts, including Sentara / Optima, Amerigroup, Anthem BCBS of VA, Coventry-Southern Health, and Virginia FFS Medicaid. Selected accomplishments: ♦ Exceeded national market share 163% by negotiating Tier I access for Premarin family of products at Sentara / Optima; maintained access for 6 consecutive years.♦ Increased sales volume 70% and secured preferred formulary status (maintained for 6 consecutive years) for Enbrel with Sentara despite aggressive contracting threat from competitor.♦ Realized 21% market share versus national market share of 15% by establishing Effexor XR as the exclusive, sole preferred antidepressant on Sentara / Optima formulary, reversing plans decision to move all brands to Tier 3 / non-formulary status through negotiating profitable access with VP of Pharmacy and building clinical support with Medical Directors.♦ Achieved 33% market share (double national average) for Protonix at Anthem BCBS of VA by leveraging strong relationship with CMO and detailing cost savings, which led to securing preferred formulary status and eventual addition to all Anthem plans nationwide.♦ Won the President’s Golden Circle Award (Top 1%; 1 out of 85) and the President’s Achievement Award (Top 5%; 4 out of 85).

Norfolk, Virginia Area

Promoted subsequent to unparalleled success in previous position, charged with promoting and selling Wyeth’s hospital products (IV antibiotics, PPIs, antidepressants, TNF inhibitors, and cardiovascular) in medical centers, community hospitals, and DOD / VA military facilities in the Mid-Atlantic States. Attained formulary access and formed trusted relationships with physician advocates to increase sales of Zosyn, Protonix, Effexor XR, Enbrel, and Altace. Primary accounts included Bethesda Naval Hospital, Walter Reed Army Medical Center, Portsmouth Naval, EVMS, and the DC/Hampton VA.Selected accomplishments: ♦ Increased sales $2 million in first year and garnered addition of Effexor XR to Basic Core Formulary within 18 months at Portsmouth Naval Medical Center by developing department head as KOL and building clinical support on P&T committee.♦ Gained addition of Protonix to Portsmouth Naval Hospital formulary despite non-formulary status on Basic (national) Core Formulary by accessing and establishing trusted relationships with key GI-department decision makers and strategically communicating clinical and financial benefits.♦ Honored with several awards during position tenure, including the Presidents Golden Circle Award (Top 1% of sales force; only 1 out of 110 peers) in 2002, Presidents Achievement Award (Top 5% of sales force; only 5 out of 110) in 2001, Area Account Manager of the Year – Mid-Atlantic Region (only 1 of 22 peers) in 2001, International Effexor XR B3 Challenge (1 of 2 winners) in 2002, and the Top Performer Award for “Altace Drive for 25” in 2002. ♦ Selected as 1 out of 22 Area Account Managers to serve as a trainer, focused on training peers on hospital account management techniques and the hospital formulary process, as well as conducting field training sessions.